

SUNDAY, 8 MAY 2011

GEC-ESTRO	EIOF	11 th Biennial	11 th Biennial	11 th Biennial
<p>Workshop</p> <p>HIGH TECH RADIOTHERAPY: WHERE DOES MODERN BRACHYTHERAPY STAND?</p> <p>Full programme available on http://www.estro-events.org/ESTROevents/Pages/gec-estroteachingcourses.aspx</p>	<p>Clinical Pre-meeting Course</p> <p>RADIOSURGERY AND STEREOTACTIC BODY RADIOTHERAPY</p> <p>Full programme available on http://www.estro-events.org/ESTROevents/Pages/estro-eventsorgESTROeventsPageseiof11-pre-meeting.aspx</p>	<p>Physics Pre-meeting Course</p> <p>NEW QUALITY MANAGEMENT APPROACHES IN RADIOTHERAPY: THE CHALLENGE TO BALANCE RESOURCES AND QUALITY FOR NEW TECHNOLOGIES AND TECHNIQUES</p> <p>Full programme available on http://www.estro-events.org/Pages/estro-eventsorgPages11thbiennial_pre-meeting.aspx</p>	<p>Physics Pre-meeting Course</p> <p>ADVANCED PHOTON BEAM DOSE DELIVERY SYSTEMS AND TECHNIQUES</p> <p>Full programme available on http://www.estro-events.org/Pages/estro-eventsorgPages11thbiennial_pre-meeting.aspx</p>	<p>RTT Pre-meeting Course</p> <p>CLINICAL MANAGEMENT, RESEARCH AND DEVELOPMENT IN RADIOTHERAPY FOR PAEDIATRIC TUMOURS</p> <p>Full programme available on http://www.estro-events.org/Pages/estro-eventsorgPages11thbiennial_pre-meeting.aspx</p>
<p>18:00 – 19:15 Opening Ceremony</p> <p>19:15 Welcome reception</p>				

CONTOURING WORKSHOPS

EIOF - CONTOURING WORKSHOPS
<p>Monday 9 May 2011 08.00 – 10.00 Lung Cancer</p>
<p>Tuesday 10 May 2011 08.00 – 10.00 Rectal Cancer</p>
<p>Wednesday 11 May 2011 08.00 – 10.00 Head and Neck Cancer</p>
<p>Thursday 12 May 2011 08.00 – 10.00 Prostate Cancer</p>


MONDAY, 9 MAY 2011

	GEC-ESTRO Room 14+15+16	GEC-ESTRO Room 6+13	EIOF Capital Hall	EIOF Room 10+11+12	11 th Biennial Physics Auditorium	11 th Biennial Physics Room 7+8+9	11 th Biennial RTT Room 2+3+4
08:00 – 08:40	<p>The future of brachytherapy: what are the potential new radionuclides?</p> <p><i>Chair: K. Tanderup (DK)</i></p> <p>D. Baltas (GR)</p>		<p>30 years of radiation oncology in Head & Neck cancer -What is the evidence that 'we' have created?</p> <p><i>Chair: TBC</i> <i>Chair: V. Budach (DE)</i></p> <p>Update of meta-analyses and EBM level 1 on Fractionation P. Blanchard (FR)</p> <p>Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck - A systematic review and meta-analysis J. Overgaard (DK)</p> <p>Update of meta-analyses and EBM level 1 on Concomitant and induction chemotherapy J. Bourhis (FR)</p>	<p>ESTRO-ESSO Joint symposium</p> <p>30 years of radiation oncology in Rectal cancer – What is the evidence-based that 'we' have created?</p> <p><i>Chair: D. de Meerleer (BE)</i> <i>Chair: J. Kazmierska (PO)</i></p> <p>Evidence from meta-analyses (short course, radiochemotherapy, adjuvant chemotherapy) D. Sebag-Montefiore (GB)</p> <p>Colorectal cancer outcome improvements in Europe: Population-based outcome registrations will conquer the world C. van de Velde (NL)</p>	<p>Image registration in radiotherapy</p> <p><i>Chair: C. Fiorino (IT)</i></p> <p>G. Rizzo (IT)</p>	<p>Advances in reference dosimetry - where do we go next?</p> <p><i>Chair: C. Clark (GB)</i></p> <p>S. Duane (GB)</p>	<p>Impact of 4DRT and RTT's role</p> <p><i>Chair: M. Mast (NL)</i></p> <p>State of ART on 4DRT – The physicist point of view J. Cuijpers (PH)</p> <p>State of ART on 4DRT – The RTT point of view H. McNair (RTT)</p>
08:45 – 10:00	<p>Evolution of MRI guided BT in cervix cancer</p> <p><i>Chairs: TP Hellebust (NO)</i> <i>Chair: J. Dimopoulos (GR)</i></p> <p>MRI-based brachytherapy in cervix cancer: where are we now? P. Petric (SL)</p> <p>Retro-EMBRACE: preliminary results of Image Guided BT for cervical cancer in the</p>	<p>Dose calculation beyond TG43: impact on clinicians and requirements from vendors</p> <p><i>Chair : L. Beaulieu (CA)</i> <i>Chair : FA Siebert (AT)</i></p> <p>INTRO: Why we should move beyond TG43 and what TG186 wants to accomplish L. Beaulieu (CA)</p> <p>SECTION I: Transport and scoring medium: status and impact R. Thomson (CA)</p>	<p>Head & Neck cancer- What is the evidence that is being created right now? - The best of clinical trials</p> <p><i>Chair: K. Składowski (PO)</i> <i>Chair: TBC</i></p> <p>The new disease: How to deal with the HPV positive and not to leave the HPV negative behind? L. Licitra (IT)</p> <p>Dose conformity and escalation: Did we</p>	<p>ESTRO-ESSO Joint symposium</p> <p>Rectal cancer - What is the evidence-based that is being created right now? - The best of clinical trials</p> <p><i>Chair: V. Valentini (IT)</i> <i>Chair: C. van de Velde (NL)</i></p> <p>Testing new treatment combination G. Lammering (NL)</p> <p>Only preoperative loco-regional and systemic</p>	<p>Functional Imaging for tumour and normal tissue characterization</p> <p><i>Chair: U. van der Heide (NL)</i> <i>Chair: TBC</i></p> <p>Functional MR imaging for delineation and characterization of prostate tumors G. Groenendaal (NL)</p> <p>Functional imaging with MRI for normal tissue response imaging Y. Cao (USA)</p>	<p>Novel dosimetry methods</p> <p><i>Chair: T. Knöös (SE)</i> <i>Chair: S. Duane (GB)</i></p> <p>3D dosimetry systems - Gels, EPIDs and others M. Duchateau (BE)</p> <p>Online luminescence dosimetry CE Andersen (DK)</p> <p>Lithium formate EPR dosimetry for dosimetry verifications in radiotherapy S. Olsson (SE)</p>	<p>From conventional to advance practice on miscellaneous treatments</p> <p><i>Chair: F. Moura (PT)</i> <i>Chair: TBC</i></p> <p>Current status on total skin electron irradiation S. Hynds (GB)</p> <p>Immobilisation methods in sarcoma treatments C. Dickie (CA)</p> <p>An Overview of CSA RT; past, present and future developments</p>

	<p>last years of the 20st Century A. Sturdza (AT)</p> <p>EMBRACE update K. Tanderup (DK)</p>	<p>Discussion</p> <p>SECTION II: Assigning the correct cross section from imaging data: why this needs to be done F. Verhaegen (NL)</p> <p>Discussion</p> <p>SECTION III: Commissioning TPS beyond TG43: Link to TG43 underlying process and going forward discussion F. Mourtada (USA)</p> <p>Discussion</p> <p>Close L. Beaulieu (CA) and FA Siebert (AT)</p>	<p>really decrease side effects and increase tumor control? C. Nutting (GB)</p> <p>Will concomitant chemo-radiation still be used in the area of EGFR inhibitors? K. Harrington (GB)</p> <p>How should we manage patients with locoregionally advanced head and neck cancer who are not suitable for chemo-radiotherapy? B. O'Sullivan (CA)</p>	<p>therapy in rectal cancer - the randomized RAPIDO trial B. Glimelius (SE)</p> <p>Testing new subgroup based tailored strategies M.A. Gambacorta (IT)</p>	<p>Imaging of residual disease in NSCLC: Towards dose painting by volumes P. Lambin (NL)</p>		H. Taylor (GB)
10:00 – 10:30	Coffee break						
10:30 – 11:45	<p>GEC Proffered Papers 1: Breast Cancer</p> <p><i>Chair: C. Polgar (HU)</i> <i>Chair: V. Strnad (DE)</i></p> <p>TWELVE YEAR CLINICAL OUTCOMES WITH INTERSTITIAL ACCELERATED PARTIAL BREAST IRRADIATION</p> <p>INTERSTITIAL HIGH DOSE RATE BRACHYTHERAPY FOR EARLY STAGE BREAST CANCER : MEDIAN 6 YEAR FOLLOW-UP OF 280 CASES USING MULTI-CATHETER TECHNIQUE</p> <p>MULTI-CATHETER HIGH DOSE RATE PARTIAL BREAST BRACHYTHERAPY: AN INNOVATIVE TECHNIQUE FOR CT-BASED IMPLANT INSERTION AND PLANNING</p> <p>HIGH-DOSE RATE BRACHYTHERAPY AS AN AMBULATORY BOOST TECHNIQUE IN BREAST CANCER : EXPERIENCE IN</p>	<p>GEC Proffered Papers 2: Prostate Toxicity</p> <p><i>Chair: J. Skowronek (PO)</i> <i>Chair: R. Laing (GB)</i></p> <p>EXTERNAL VALIDATION OF THE PRE-TREATMENT NOMOGRAM TO PREDICT ACUTE URINARY RETENTION AFTER I-125 PROSTATE BRACHYTHERAPY</p> <p>URETHRA-SPARING, INTRA-OPERATIVE, REAL-TIME PLANNED, PERMANENT-SEED PROSTATE BRACHYTHERAPY: TOXICITY ANALYSIS</p> <p>DOSIMETRIC ANALYSIS OF URETHRAL STRICTURES FOLLOWING HDR MONOTHERAPY FOR ADENOCARCINOMA OF THE PROSTATE</p> <p>PREVIOUS TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) IS NOT A CONTRAINDICATION FOR INTERSTITIAL HIGH DOSE RATE (HDR) BRACHYTHERAPY FOR</p>	<p>Head & Neck cancer - Vision for the future: What 'we' will ask for in the new grant applications?</p> <p>Biological and image guided adaptive radiotherapy :</p> <p><i>Chair: G. Calais (FR)</i> <i>Chair: R. Corvo (IT)</i></p> <p>Understanding and taking advantage of the tumor biology RH. Brakenhoff (NL)</p> <p>Localize the enemy: Imaging in H&N cancer V. Gregoire (BE)</p> <p>Adaptive radiation treatment of head and neck cancer in the future – advanced treatment planning and delivery C. Grau (DK)</p>	<p>ESTRO-ESSO Joint symposium</p> <p>Vision for the future: What 'we' will ask for in the new grant applications? - Translational research / High technology</p> <p><i>Chair: V. Valentini (IT)</i> <i>Chair: C. van de Velde (NL)</i></p> <p>Adaptive radiotherapy in rectal cancer: future or futile? C. Marijnen (NL)</p> <p>Adaptive radiotherapy by molecular imaging changes K. Haustermans (BE)</p> <p>Adaptive radiotherapy by predictive biological markers C. Roedel (DE)</p>	<p>Physics Proffered Papers 1: Response Prediction: Geometry and Precision</p> <p><i>Chair: DR Olsen (NO)</i> <i>Chair: E. Spezi (GB)</i></p> <p>ADAPTATION OF RADIOTHERAPY TO A SHRINKING MACROSCOPIC TUMOR IN ADVANCED STAGE NSCLC DOES NOT UNDERDOSE THE MICROSCOPIC DISEASE AND HAS THE POTENTIAL TO INCREASE TUMOR CONTROL PROBABILITY</p> <p>THE IMPACT OF MICROSCOPIC DISEASE ON THE TCP IN NSCLC</p> <p>TCP LOSS DUE TO SETUP ERRORS AS A FUNCTION OF DOSE-RESPONSE SLOPE AND NUMBER OF FRACTIONS</p> <p>QUANTITATIVE PARAMETERS OF PAROTID DEFORMATION ARE HIGHLY CORRELATED TO DVH: EVIDENCE OF A DOSE-BATH</p>	<p>Physics Proffered Papers 2: Basic Dosimetry</p> <p><i>Chair: N. Jornet (ES)</i> <i>Chair: K. Venables (GB)</i></p> <p>PERIPHERAL GAMMA DOSE AND THERMAL NEUTRON FLUENCIES EVALUATION IN DIFFERENT MATERIALS FOR IMRT</p> <p>RE-ESTABLISHING THE PHOTON ABSORBED DOSE PRIMARY STANDARD ON THE NPL CLINICAL LINAC</p> <p>SENSITIVITY OF THE CORRECTION FACTOR FOR USE IN REFERENCE DOSIMETRY OF NONSTANDARD BEAMS TO DOSE HOMOGENEITY</p> <p>APPLICATION OF A NEW FORMALISM FOR REFERENCE DOSIMETRY IN TOMOTHERAPY FOR THREE CYLINDRICAL IONIZATION CHAMBERS</p> <p>HOW ACCURATE ARE</p>	<p>RTT Proffered Papers 1: Professional Development and Risk Management</p> <p><i>Chair: M. Litoborski (PO)</i> <i>Chair: K. Baldwin (GB)</i></p> <p>FIRST RESULTS OF A WORLDWIDE SURVEY ON RESPONSIBILITIES AND RESOURCES IN MODERN RADIATION THERAPY</p> <p>A UK APPROACH TO PATIENT SAFETY IN RADIOTHERAPY: HPA INITIATIVES</p> <p>PATIENT EDUCATION IN 3D - THIS IS HOW RADIATION THERAPY IS DONE</p> <p>SEVEN YEAR REVIEW OF A RADIOTHERAPY INCIDENT REPORTING AND LEARNING SYSTEM</p> <p>HOW MUCH EXPERIENCE IS ENOUGH? A COMPARATIVE ANALYSIS OF IMRT PLANS</p>

	<p>502 PATIENTS</p> <p>A SAFE AND PREDICTABLE METHOD OF DELIVERING THERMAL BOOST COMBINED WITH HDR BRACHYTHERAPY IN CONSERVATIVE MANAGEMENT OF BREAST CANCER</p> <p>LOCALISATION OF THE SURGICAL CAVITY USING SUPINE MAGNETIC RESONANCE AND COMPUTED TOMOGRAPHY SCAN FUSION FOR PLANIFICATION OF BREAST INTERSTITIAL BRACHYTHERAPY</p> <p>BREAST TISSUE MODELING IN MONTE CARLO POST-IMPLANT EVALUATION OF BREAST LDR BRACHYTHERAPY</p>	<p>PROSTATE CANCER</p> <p>OBJECTIVE BASELINE PARAMETERS INFLUENCE ON URINARY SIDE EFFECTS AFTER BRACHYTHERAPY OF THE PROSTATE</p> <p>DOSE ESCALATION WITH IMRT TECHNIQUE VERSUS IMRT + HDR BRT IN PATIENTS WITH HIGH RISK CARCINOMA OF THE PROSTATE – COMPARISON OF ACUTE TOXICITY</p> <p>PREDICTORS FOR PERSISTENT OBSTRUCTIVE URINARY SYMPTOMS REQUIRING A TURP AFTER BRACHYTHERAPY OF THE PROSTATE</p>			<p>EFFECT AROUND 15GY</p> <p>APPROACHING THE TRUE DVH TO IMPROVE PREDICTION OF TOXICITY - A RECTAL MOTION SIMULATION STUDY</p> <p>USING LONGITUDINAL AND CIRCUMFERENTIAL PARAMETERS FROM ESOPHAGUS SURFACE DOSE DISTRIBUTIONS TO PREDICT ACUTE ESOPHAGITIS AFTER CONCURRENT CHEMO-IMRT FOR LUNG CANCER</p> <p>VALIDATION OF THE LQL MODEL FOR NTCP PREDICTION IN LUNG CANCER PATIENTS TREATED WITH SBRT</p>	<p>MONTE CARLO CALCULATED KQ FACTORS FOR EXTERNAL BEAM RADIOTHERAPY?</p> <p>SCINTILLATION DOSIMETRY IN EXTERNAL BEAM RADIATION THERAPY: REVIEW AND COMPARATIVE ANALYSIS OF THREE APPROACHES</p> <p>DOSE TO MEDIUM AND WATER IN LOW ENERGY BRACHYTHERAPY</p>	<p>INVESTIGATING THE FACTORS THAT INFLUENCE JOB SATISFACTION AT THE START OF A THERAPY RADIOGRAPHERS CAREER</p> <p>NATIONAL INCIDENT REPORTING AND LEARNING SYSTEM</p>
11:50–13:00	<p><i>Chair: J. Bourhis (FR)</i> <i>Chair: V. Valentini (IT)</i></p> <p>Anniversary Plenary Lecture ESTRO - 30 YEARS IN 30 MINUTES J. Overgaard (DK)</p> <p>Honorary Physicist Award Lecture From mathematical models to real biology: research at the interface of physics and biology in radiotherapy A. van der Kogel (NL)</p> <p>Accuray Clinical: DOSIMETRIC COMPARISON OF LIVER TUMOUR RADIOTHERAPY IN ALL RESPIRATORY PHASES AND IN ONE PHASE USING 4DCT D. Gabrys (PO)</p>						
13:00 – 14:45	Satellite symposium Accuray	Lunch, Satellite Symposia, Poster Viewing			Satellite symposium Elekta	Satellite symposium Sun Nuclear	
14:45 – 16:15	<p>Are there (re)new indications for brachytherapy?</p> <p><i>Chair: C. Haie-Meder (FR)</i> <i>Chair: P. Petric (SL)</i></p> <p>Brachytherapy of the liver G. Gademann (DE)</p> <p>What remain the best indications for brachytherapy in head and neck cancers? G. Kovacs (DE)</p> <p>MRI guided robotics in</p>	<p>Session on EU projects</p> <p>Risks to normal tissue from current and emerging radiotherapy modalities: the results and recommendations of the ALLEGRO Project</p> <p>14:45: Introduction: An overview of the ALLEGRO Project. A. Ottolenghi (IT)</p> <p>14:55 Dosimetry for</p>	<p>New frontiers in metastatic cancers</p> <p><i>Session developed in collaboration with ASCO and ESMO</i></p> <p>ASCO <i>Chair: M. Gospodarowicz (CA)</i> ESTRO <i>Chair: M. Verheij (NL)</i></p> <p>New therapeutic targets for advanced lung cancer EGFR and EML4/ALK JC Soria (FR)</p> <p>Improving the outcome</p>	<p>Clinical Proffered Papers 1: Head and Neck</p> <p><i>Chair: J. Giralt (ES)</i> <i>Chair: R. Miralbell (CH)</i></p> <p>THE INFLUENCE OF COMORBIDITY, SMOKING BEHAVIOUR AND HUMAN PAPILLOMAVIRUS ON OVERALL SURVIVAL IN 1091 PATIENTS WITH OROPHARYNGEAL CARCINOMA: THE DAHANCA EXPERIENCE</p> <p><i>Discussant: W. Budach (DE) – 5 min</i></p> <p>EXPRESSION OF THE EPIDERMAL GROWTH</p>	<p>Intra-fraction challenges – Equipment</p> <p><i>Chair: T. Piotrowski (PO)</i> <i>Chair: C. Stacey (GB)</i></p> <p>New technologies for the management of organ motion D. Verellen (BE)</p> <p>Radiotherapy systems with integrated MRI functionality for direct, intra-fraction tumour tracking B. Raaymakers (NL)</p>	<p>New developments and innovative approaches</p> <p><i>Chair: U. Oelfke (DE)</i> <i>Chair: P. Evans (GB)</i></p> <p>Pre-clinical assessment of radiation response: Technology and results from a small animal irradiation facility J. Wong (USA)</p> <p>Intensity Modulated CT D. Jaffray (CA)</p> <p>Phase contrast imaging: towards</p>	<p>Joint with Physics</p> <p>Safety in radiation therapy</p> <p><i>Chair: J. Malicki (PO)</i> <i>Chair: D. Georg (AT)</i></p> <p>International incident reporting: lessons from ROSIS J. Cunningham (IE)</p> <p>Preventing Accidental Exposures from New External Beam Radiation Therapy Technologies (ICRP report)</p>

	Brachytherapy R. Moerland (NL)	<p>normal tissue risk assessment: Measurement and calculation of the doses received by normal tissues from radiation therapy from current and emerging modalities. F. Van den Heuvel (BE)</p> <p>15:15 NTCP modelling. Current model development, fitting, validation, and applications. H. Langendijk (NL)</p> <p>15:35 Second cancers after radiation therapy; Potential and pitfalls of the analyses of clinical databases W. Dörr (DE)</p> <p>15:55 Conclusions and Recommendations: lessons learned for clinical practice, policy makers, equipment manufacturers, prospective data collection, and questions remaining for future research. M. Baumann (DE)</p> <p>16:15 Close</p>	with curative high precision radiotherapy for metastatic patients? E. Lartigau (FR)	<p>Abscopal immune response linked to radiotherapy S. Formenti (USA)</p> <p>Can small doses of radiation enhance chemotherapy in advanced patients? V. Valentini (IT)</p>	<p>FACTOR PREDICTS THE EFFECT OF HYPOXIA MODIFICATION AS AN ADDITIVE TO ACCELERATED RADIOTHERAPY OF LARYNGEAL CANCER IN A RANDOMIZED TRIAL <i>Discussant: N. Slevin (GB) – 5 min</i></p> <p>DIAGNOSTIC PERFORMANCE OF FDG-PET(CT) FOR POST-TREATMENT RESTAGING OF HEADNECK CANCERS: A META-ANALYSIS</p> <p>XEROSTOMIA PATIENT REPORTED OUTCOMES ARE A LINEAR FUNCTION OF CONTRALATERAL PAROTID GLAND MEAN DOSE</p> <p>LONG TERM RESULTS OF THE GORTEC 2000-01 LARYNX PRESERVATION RANDOMISED TRIAL, USING A COMPOSITE FUNCTIONAL ENDPOINT</p> <p>RISK FACTORS FOR SWALLOWING DYSFUNCTION AFTER RADIOTHERAPY IN THE DAHANCA 6 & 7 RANDOMIZED TRIAL</p> <p>ARE ALL TECHNIQUES ALIKE? A COMPARISON OF THREE ROTATIONAL IMRT TECHNIQUES FOR HEAD-AND-NECK CANCER. <i>Discussant: W. Verbakel (NL) – 5 min</i></p>	Marker-based and marker-less navigation in Cyberknife Radiosurgery A. Schweikard (DE)	clinical application A. Bravin (FR)	O. Holmberg (AT) The role of education and training in providing safe radiotherapy M. do Carmo Lopes (PT)
16:15 – 16:45	Coffee break							
16:45 – 18:00	<p>GEC Proffered Papers 3: Cervix Cancer <i>Chair: LT Tan (GB)</i> <i>Chair: R. Mazon (FR)</i></p> <p>MULTICENTRE STUDY OF MRI-GUIDED BRACHY THERAPY</p>	<p>GEC Proffered Papers 4: Brachytherapy Physics <i>Chair: A. Rijnders (BE)</i> <i>Chair: B. Al-Qaisieh (GB)</i></p> <p>CHALLENGES AND</p>	<p>ESTRO – JASTRO Joint symposium</p> <p>What is the level of evidence needed in Particle Therapy? <i>Chair: M. Hiraoka (JP)</i></p>	<p>Clinical Proffered Papers 2: Rectal Cancer <i>Chair: F. Calvo (ES)</i> <i>Chair: D. Tait (GB)</i></p> <p>POSTOPERATIVE CHEMORADIOTHERAPY IMPROVES SURVIVAL AFTER</p>	<p>Physics Proffered Papers 3: Highlights <i>Chair: B. Mijnheer (NL)</i> <i>Chair: J. Warrington (GB)</i></p> <p>REALIZATION OF THE ABSORBED DOSE TO WATER FOR I-125 INTERSTITIAL</p>	<p>Physics Proffered Papers 4: Dose Volume Parameters and Biological Modelling <i>Chair: A. Gulyban (BE)</i> <i>Chair: I. Rosenberg (GB)</i></p>	<p>RTT Proffered Papers 2: Head and Neck Cancer Treatment <i>Chair: M. Peszynska (PO)</i> <i>Chair: S. Faithfull (GB)</i></p>	

	<p>TREATMENT PLANNING: COMPARISON AMONG TANDEM OVOID APPLICATOR USERS</p> <p>LOCAL RECURRENCES IN CERVICAL CANCER PATIENTS IN THE SETTING OF MRI-GUIDED BRACHYTHERAPY: A COMPARISON OF SPATIAL DOSE DISTRIBUTION WITHIN A MATCHED-PAIR ANALYSIS</p> <p>FEASIBILITY OF APPLYING ONE TREATMENT PLAN FOR SUCCEEDING FRACTIONS IN IMAGE GUIDED BRACHYTHERAPY IN CERVIX CANCER</p> <p>EFFECTS OF FULL VS EMPTY BLADDER ON TOTAL EQUIVALENT DOSE TO ORGANS AT RISK IN 3D IMAGE-BASED PLANNING OF HIGH-DOSE-RATE INTRACAVITARY BRACHYTHERAPY FOR CERVICAL CANCER</p> <p>ANALYSIS OF SPATIAL AGREEMENT BETWEEN CT (+PREBT MRI) AND MRI BASED HRCTV DELINEATION IN CERVIX CANCER BRACHYTHERAPY</p> <p>DOSIMETRIC AND CLINICAL RESULTS OF A FRENCH PROSPECTIVE STUDY OF 3D BRACHYTHERAPY FOR CERVIX CARCINOMA</p> <p>A 3D PROBABILITY MAP OF THE HR-CTV OF CERVICAL TUMOURS AT TIME OF BRACHYTHERAPY WITH A TANDEM AND OVOID APPLICATOR</p>	<p>REQUIREMENTS FOR THE INTRODUCTION OF MODEL-BASED DOSE CALCULATION ALGORITHMS IN BRACHYTHERAPY: A STATUS UPDATE FROM AAPM TASKGROUP 186</p> <p>ON THE POTENTIAL OF DUAL ENERGY CT TISSUE SEGMENTATION IN LOW ENERGY BRACHYTHERAPY DOSE CALCULATIONS</p> <p>MONTE CARLO DOSIMETRY OF HIGH DOSE RATE GYNECOLOGIC INTERSTITIAL BRACHYTHERAPY</p> <p>4D U/S-BASED PROSTATE HDR BRACHYTHERAPY TREATMENT PLANNING: ANALYSIS OF INFLUENCE OF PATIENT MOVEMENT AND ANATOMY ALTERATION ON THE PLAN QUALITY AND TREATMENT DELIVERY</p> <p>SYSTEMATIC ERRORS IN SOURCE POSITION AND ORIENTATION IN RING APPLICATORS. DO THEY MATTER?</p> <p>COMPENSATOR-BASED INTENSITY MODULATED BRACHYTHERAPY</p> <p>INTER FRACTION VARIATION OF HIGH DOSE REGIONS IN OAR IN MR IMAGE BASED CERVIX BRACHYTHERAPY USING RIGID REGISTRATION</p>	<p><i>Chair: J. Bourhis (FR)</i></p> <p>Debate: We do not need randomized trials to demonstrate that proton is superior to X-rays therapy</p> <p>For the motion: Considerable difficulty in RCTS with proton beam therapy – which cancer status is appropriate? H. Sakurai (Japan)</p> <p>Against the motion: Is proton therapy magic? W Robert Lee (USA)</p> <p>Tumor sites to be selected for comparison of carbon ions vs protons? H Tsujii (JP)</p> <p>What tumor sites should be selected for randomized trials? J. Debus (DE)</p>	<p>D1 LYMPHADENECTOMY OR R1 RESECTION IN GASTRIC CANCER</p> <p>GASTRIC MALT LYMPHOMA: LONG-TERM EXCELLENT OUTCOME OF 103 PATIENTS TREATED WITH RADIOTHERAPY ALONE</p> <p>PREOPERATIVE RADIOTHERAPY AND LOCAL EXCISION OF RECTAL CANCER: RESULTS OF A RANDOMIZED STUDY K. Bujko (PO)</p> <p>THE ADDED VALUE OF TEXTURE- AND SHAPE-BASED FEATURES FROM CT-IMAGING FOR RESPONSE PREDICTION IN LOCALLY ADVANCED RECTAL CANCER</p> <p>TARGET VOLUME DELINEATION VARIATION IN PRE-OPERATIVE RADIOTHERAPY OF EARLYSTAGE RECTAL CANCER</p> <p>TOWARDS A LYON MOLECULAR PROGNOSTIC SIGNATURE FOR RECTAL CANCER</p>	<p>BRACHYTHERAPY SOURCES</p> <p>NORMAL TISSUE REACTION OF THE LIVER AFTER STEREOTACTIC RADIOTHERAPY (SBRT) DETERMINED BY 18-FLUORODEOXYGALACTOSE AND PET/CT-SCANNING</p> <p>PROCARE /RT PART/: IMPROVING CARE OF RECTAL CANCER IN BELGIUM BY STANDARDIZING CTV DELINEATION</p> <p>ENHANCED 4D PET OPTIMIZATION BASED ON 4D CT MOTION MODELING</p> <p>DEVELOPMENT OF A COMPREHENSIVE ONLINE ADAPTIVE SOLUTION TO ACCOUNT FOR INTERAND INTRA-FRACTIONAL VARIATIONS</p>	<p>DOSE MAPPING BASED ON DEFORMABLE REGISTRATION TO RELATE DOSE OUTSIDE THE PROSTATE WITH FAILURE</p> <p>FOCUSING ON A LONGITUDINAL DEFINITION OF LATE FECAL INCONTINENCE AFTER HIGHDOSE RADIATION FOR PROSTATE CANCER: A STRONGER EVIDENCE OF CLINICAL AND DOSIMETRIC PREDICTORS</p> <p>LACK OF CORRELATION BETWEEN DVH SPECIFIC ENDPOINTS FOR OAR AND LATE TOXICITY FOR PROSTATE CANCER PATIENTS TREATED WITH IMRT</p> <p>COMBINING DOSE-VOLUME INFORMATION AND PATIENT CO-MORBIDITIES FOR PREDICTING RADIATION INDUCED PNEUMONITIS</p> <p>EXPLORING THE BIOLOGICAL BASIS FOR THE MECHANISTIC MODELLING OF RADIATION PNEUMONITIS</p> <p>ESTIMATED LIFE YEARS LOST DUE TO FATAL LATE COMPLICATIONS AFTER PHOTON OR PROTON RADIOTHERAPY</p> <p>EORTC RADIOTHERAPY QUALITY ASSURANCE PLATFORM: ESTABLISHMENT OF AN INTEGRATED CENTRAL REVIEW FACILITY</p>	<p>IS THERE A CORRELATION BETWEEN SMOKING AND LATE SIDE EFFECTS FOR HEAD AND NECK CANCER PATIENTS?</p> <p>DYSPHAGIA REDUCTION WITH OPTIMIZED PHOTON AND PROTON INTENSITY-MODULATED RADIOTHERAPY FOR HEAD AND NECK CANCER</p> <p>QUALITY OF LIFE ASSESSMENT IN EARLY STAGES GLOTTIS CANCER PATIENTS WHO ARE IN THE FOLLOW-UP PERIOD</p> <p>ASSESSMENT OF HEAD AND NECK IMMOBILIZATION DEVICE FOR ACCURATE RAPIDARC® TR EATMENT DELIVERY</p> <p>DOSIMETRIC EVALUATION OF A THREE-PHASE ADAPTIVE RADIOTHERAPY FOR NASOPHARYNGEAL CANCER USING HELICAL TOMOTHERAPY</p> <p>DOSE PAINTING BY NUMBERS FOR HEAD AND NECK CANCER: 18F-FDG-PET-VOXEL INTENSITYBASED VMAT VERSUS 18F-FDG-PET-VOXEL INTENSITY-BASED IMRT</p> <p>DOSIMETRIC AND RADIOBIOLOGIC EVALUATION OF BIOLOGICALLY ADAPTED IMRT</p>
18:00 –	<p>Poster Reception Physicist Poster Award RTT Poster Award Clinical Poster Award GEC-ESTRO Best Poster Award</p> <div style="text-align: center;">  <p>Poster Area</p> </div>						

TUESDAY, 10 MAY 2011

	GEC-ESTRO Room 14+15+16	GEC-ESTRO Room 6+13	EIOF Capital Hall	EIOF Room 10+11+12	11 th Biennial Physics Auditorium	11 th Biennial Physics Room 7+8+9	11 th Biennial RTT Room 2+3+4
08:00 – 08:40	<p>Publications of brachytherapy articles: overview and current trends with focus on 'Radiotherapy and Oncology'</p> <p><i>Chair: P. Blanchard (FR)</i></p> <p>R. Pötter (AT)</p>		<p>30 years of radiation oncology in Lung cancer- What is the evidence that 'we' have created? – Update on randomized trials and Meta-analyses</p> <p><i>Chair: P. Thirion (IE)</i> <i>Chair: V. Atkocius (LT)</i></p> <p>The controversy of modified fractionation regimens M. Saunders (GB)</p> <p>Update on randomized trials and Meta-analyses concerning Induction versus Concomitant radiochemotherapy in lung cancer C. Le Pechoux (FR)</p>	<p>30 years of radiation oncology in Breast cancer - What is the evidence that 'we' have created? – Update on randomized trials and Meta-analyses</p> <p><i>Chair: A. Barrett (GB)</i> <i>Chair: B. Offersen (DK)</i></p> <p>Radiotherapy after breast-conserving surgery in early breast cancer: update from the early breast cancer trialists' collaborative group S. Darby (GB)</p> <p>Radiation-related heart disease following treatment for breast cancer C. Taylor (GB)</p>	<p>Volumetric Imaging: Adaptive Radiotherapy Strategies for Clinical Implementation</p> <p><i>Chair: M. van Herk (NL)</i></p> <p>V. Khoo (GB)</p>	<p>A critical overview of arc therapy techniques</p> <p><i>Chair: S. Vynckier (BE)</i></p> <p>T. Bortfeld (USA)</p>	<p>Image-guided adaptive Radiation Therapy – more than a verification tool</p> <p><i>Chair: H. McNair (GB)</i></p> <p>J.J. Sonke (NL)</p>
08:45 – 10:00	<p>The necessity of quality assurance in brachytherapy</p> <p><i>Chair: FA Siebert (DE)</i> <i>Chair: M. De Brabandere (BE)</i></p> <p>Accidents in LDR and HDR brachytherapy J-M Cosset (FR)</p> <p>Emergency procedures: is your life jacket ready - or will you learn to swim when landing on water? A. Rijnders (BE)</p> <p>Quality assurance in brachytherapy B. Al-Qaisieh (GB)</p>		<p>ESTRO-ESTS-ERS Joint session</p> <p>Lung Cancer - What is the evidence that is being created right now? - The best of clinical trials - Early stage NSCLC</p> <p><i>Chair: J. Eriksen (DK)</i> <i>Chair: U. Riccardi (IT)</i></p> <p>Limited resection H. J. Hansen (DK)</p> <p>Stereotactic RT: The new standard for high-risk patients with stage 1 NSCLC F. Lagerwaard (NL)</p> <p>High frequency ablation</p>	<p>Breast cancer - What is the evidence that is being created right now? - The best of clinical trials</p> <p><i>Chair: D. Hollywood (IE)</i> <i>Chair: J. Overgaard (DK)</i></p> <p>Update and status report on hypofractionation and acceleration (START and Canadian study) T. Whelan (CA)</p> <p>Update of three major Phase III randomized trials from the EORTC Breast and Radiotherapy group</p>	<p>Intra-fraction challenges – Prediction models</p> <p><i>Chair: D. Verellen (BE)</i> <i>Chair: J. Bedford (GB)</i></p> <p>Management of breathing motion through multileaf collimator tracking A. Krauss (DE)</p> <p>Yet another approach to pursue a moving tumor: the gimbaled linear accelerator system T. Depuydt (BE)</p> <p>Real-time respiratory tumour tracking by a robotic system</p>	<p>QA for rotational therapy</p> <p><i>Chair: M. Stock (AT)</i> <i>Chair: G. Baker (GB)</i></p> <p>QA for Tomotherapy, proposals of the Task Group 148 of the AAPM S. Vynckier (BE) (on behalf of TG148)</p> <p>EPID-based quality assurance for volumetric modulated arc therapy. L. Hoffmann (DK)</p> <p>Specific QA issues for Tomotherapy: introduction of new QA tools V. Althof (NL)</p>	<p>IMRT planning and verification</p> <p><i>Chair: M. Leech (IE)</i> <i>Chair: J. Cashmore (GB)</i></p> <p>Does inverse planned intensity modulation in breast radiotherapy bring any clinical benefit? H. Van der laan (NL)</p> <p>VMAT vs. conventional IMRT techniques for SBRT of lung cancer A. Holt (NL)</p> <p>Guidelines for the verification of IMRT D. Georg (AT)</p>

			<p>T. DeBaere (FR)</p> <p>Role of adjuvant chemotherapy J-P Sculier (BE)</p> <p>Radiobiology and molecular response imaging in hypofractionation J. Bussink (NL)</p>	<p>H. Bartelink (NL) M. Donker (NL)</p> <p>Evaluation of radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 25-year update of the Danish Breast Cancer Cooperative Group DBCG 82b&c Trial M. Overgaard (DK)</p>	<p>M. Hoogeman (NL)</p>	<p>QA for Volumetric-modulated arc therapy at the NKI-AVL A. Mans (NL)</p>	
10:00 – 10:30	Coffee break						
10:30 – 11:45	<p>GEC Proffered Papers 5: Brachytherapy in anal, rectal, bladder and soft tissue sarcomas</p> <p><i>Chairs: E. Van Limbergen (BE) Chair: A. Sun Myint (GB)</i></p> <p>PULSED DOSE RATE BRACHYTHERAPY OF ANAL CARCINOMA: RETROSPECTIVE DATA WITH LONG TERM FOLLOW-UP</p> <p>REAL-TIME 3D TREATMENT PLANNING FOR IMAGE INTERSTITIAL ADAPTED HDR BRACHYTHERAPY (IABT) BOOST IN ANAL CANCER</p> <p>DOSE ESCALATION WITH CONTACT X-RAY (CXRT) AND ORGAN PRESERVATION IN RECTAL CANCER. LYON R96-02 RANDOMIZED TRIAL</p> <p>HIGH DOSE RATE ENDORECTAL BRACHYTHERAPY BOOST IN TREATMENT OF MEDICALLY UNFIT PATIENTS TO UNDERGO SURGERY FOR RECTAL CANCER</p> <p>DA VINCI CURIE CONNECTION. EARLY EXPERIENCE OF LAPAROSCOPIC/ ROBOT ASSISTED BRACHYTHERAPY IMPLANTATIONS (LBI) IN SOLITARY BLADDER CANCER</p> <p>TOXICITY, PATTERNS OF FAILURE & OUTCOME IN</p>	<p>GEC Proffered Papers 6: Prostate</p> <p><i>Chair: JM Cosset (FR) Chair: A. Henry (GB)</i></p> <p>Best Junior Presentation</p> <p>PROSTATE POST-IMPLANT DOSIMETRY: INTEROBSERVER VARIABILITY IN SEED LOCALISATION, CONTOURING & FUSION</p> <p>RESULTS AFTER 8 YEARS OF CURATIVE I-125 BRACHYTHERAPY IN 1023 CONSECUTIVE PATIENTS WITH LOW, INTERMEDIATE AND HIGH RISK PROSTATE CANCER</p> <p>LONG TERM RESULTS OF A PROSPECTIVE DOSE ESCALATION PHASE-II TRIAL: INTERSTITIAL PDR-BRACHYTHERAPY AS BOOST FOR INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER</p> <p>INTERSTITIAL HIGH DOSE RATE (HDR) BRACHYTHERAPY + IMRT VS. HDR MONOTHERAPY: MEDIAN 8 YEAR FOLLOW-UP IN 428 PATIENTS</p> <p>CLINICAL OUTCOMES COMPARISON FOR PROSTATE CANCER PATIENTS WITH LOW/INTERMEDIATE RISK FACTORS TREATED SEQUENTIALLY WITH 2 HIGH DOSE RATE BRACHYTHERAPY SCHEDULES</p>	<p>ESTRO-ESTS-ERS</p> <p>Joint session</p> <p>Lung Cancer - Vision for the future: What 'we' will ask for in the new grant applications? -</p> <p>Translational research / High technology</p> <p><i>Chair: RO Mirimanoff (CH) Chair: R. Engenhart-Cabillic (DE)</i></p> <p>PET imaging for dose-escalation in NSCLC D. De Ruyscher (NL)</p> <p>Protons compared to X-IMRT compared to 3D in locally advanced NSCLC R. Komaki (USA)</p> <p>Biological Prediction for Molecular Targeting in Radiotherapy of NSCLC M. Baumann (DE)</p>	<p>Breast cancer - Vision for the future: What 'we' will ask for in the new grant applications? -</p> <p>Translational research / High technology</p> <p><i>Chair: S. Turkan (TR) Chair: JW Leer (NL)</i></p> <p>The genetic and epigenetic influence on radiation response TBC</p> <p>Partial breast radiotherapy: What do we need to know? J. Yarnold (GB)</p> <p>Interaction with systemic therapy A. Fourquet (FR)</p>	<p>Physics Proffered papers 5: Strategy and Developments in IGRT</p> <p><i>Chair: A. Nisbet (GB) Chair: D. Jaffray (USA)</i></p> <p>INCLUSION OF CONE BEAM COMPUTED TOMOGRAPHY DOSE IN THE OPTIMIZATION OF A TREATMENT PLAN</p> <p>GEOMETRIC ADAPTATIONS TO AN ELECTRON GUN DESIGN FOR USE IN AN IN-LINE MRI-LINAC</p> <p>DISTORTION FREE MR IMAGES FOR IGRT ON THE MRI-ACCELERATOR</p> <p>A NOVEL APPROACH TO LINAC-MOUNTED INTRA-FRACTIONAL X-RAY IMAGING FOR MOTION MANAGEMENT</p> <p>BETWEEN GOLD STANDARD AND REALITY: IMAGE GUIDED ADAPTIVE BRACHYTHERAPY FOR CERVICAL CANCER PATIENTS, WITH MRI ONLY AT FIRST FRACTION</p> <p>INTEGRATED ON-BOARD CBCT-ULTRASOUND IGRT OF SOFT TISSUE TARGETS</p> <p>CAPABILITIES AND INHERENT LIMITATIONS OF OPTICAL BODY SURFACE SENSING USING FOURIER PROFILOMETRY</p>	<p>Physics Proffered Papers 6: IGRT: 4D and Breathing Adapted</p> <p><i>Chair: TBC Chair: P. Mayles (GB)</i></p> <p>COMPARISON OF DIFFERENT STRATEGIES FOR RESPIRATORY MOTION CORRECTION OF CONEBEAM CT IN LUNG CANCER SBRT</p> <p>4D-CT RECONSTRUCTION USING MV PORTAL IMAGING DURING VOLUMETRIC MODULATED ARC THERAPY</p> <p>THE USE OF A GLOBAL RESPIRATORY MOTION MODEL FOR REAL TIME 4D RADIO THERAPY APPLICATIONS</p> <p>4DCT HIGH QUALITY IMAGING AND CONTRAST ENHANCEMENT FOR 3D RADIO THERAPY TREATMENT PLANNING</p> <p>MV IMAGE-BASED DYNAMIC MLC TRACKING OF A NITISTENT IN PIG LUNGS ON A LINEAR ACCELERATOR</p> <p>LOW DOSE FLUOROSCOPY BASED DETECTION OF IMPLANTED MARKER POSITION ON THE VERO SYSTEM FOR REAL-TIME TUMOR TRACKING</p> <p>GEOMETRIC ACCURACY OF DYNAMIC MLC TRACKING WITH AN IMPLANTABLE WIRED ELECTROMAGNETIC TRANSPONDER</p>	<p>RTT Proffered Papers 3: Treatment Planning and Delivery</p> <p><i>Chair: R. Harris (GB) Chair: F. Carruthers (BE)</i></p> <p>DOES DOSE RATE AND GANTRY SPEED PROVIDE SUFFICIENT DEGREES OF FREEDOM TO ALLOW FOR MULTI-CRITERIA VMAT PLANNING?</p> <p>CLINICALLY RELEVANT PARETO FRONTS</p> <p>ROBUST OPTIMIZATION ACCOUNTING FOR ORGAN MOTION, RANGE ERRORS, AND SETUP ERRORS IN IMPT</p> <p>SBRT WITH VARIAN TRUEBEAM: TIME-EFFICIENCY AND PATIENT STABILITY</p> <p>TOMOTHERAPY AND INTENSITY MODULATED PROTON THERAPY IN THE TREATMENT OF DOMINANT INTRAPROSTATIC LESION</p> <p>FEASIBILITY OF DOSE DIFFERENCE ASSESSMENTS FOR ADAPTIVE RADIO THERAPY IN ROUTINE PRACTICE WITH TOMOTHERAPY</p> <p>PROBABILISTIC PLANNING REDUCES NORMAL TISSUE COMPLICATION PROBABILITIES IN PROSTATE IMRT PLANS</p>


	SOFT TISSUE SARCOMAS TREATED WITH PERIOPERATIVE HDR BRACHYTHERAPY & EBRT	MODERATE DOSE ESCALATION WITH SINGLE-FRACTION HIGH-DOSE-RATE BRACHYTHERAPY BOOST FOR CLINICALLY LOCALIZED INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER: FIVEYEAR OUTCOME OF THE FIRST 100 CONSECUTIVELY TREATED PATIENTS IS SINGLE FRACTION 15 GY THE PREFERRED BOOST DOSE FOR PROSTATE CANCER?					
11:50 – 13:00	<p><i>Chair: G. Kovács (DE)</i> <i>Chair: J. Malicki (PL)</i></p> <p>Iridium Award Lecture INTRODUCTION G. Kovács (DE)</p> <p>THE TRUTH ON PERMANENT PROSTATE BRACHYTHERAPY JJ Battermann (NL)</p> <p>Varian-Physics, Accuray-Physics and Jack-Fowler Physics award lectures</p> <p>Varian-Physics: UNDERSTANDING XEROSTOMIA: THE ROLE OF MRI TO VISUALIZE EARLY RADIATION-INDUCED CHANGES IN SALIVARY GLANDS A. Houweling (NL)</p> <p>Varian-Physics: RADIOTHERAPY WITH UNFLATTENED PHOTON BEAMS: DOSIMETRIC ACCURACY OF TREATMENT PLANNING SYSTEMS G. Kragl (AT)</p> <p>Accuray-Physics: A COVERAGE PROBABILITY BASED METHOD TO ESTIMATE PATIENT-SPECIFIC SMALL BOWEL PLANNING VOLUMES FOR USE IN RADIOTHERAPY LB Hysing (NO)</p> <p>Jack-Fowler Physics TEMPORAL CHARACTERISATION AND IN-VITRO COMPARISON OF CELL SURVIVAL FOLLOWING DELIVERY OF 3D-CONFORMAL, INTENSITY MODULATED RADIATION THERAPY (IMRT) AND VOLUMETRIC MODULATED ARC THERAPY (VMAT) C. McGarry (GB)</p>						
13:00 – 14:45	Satellite symposium TomoTherapy	13:00-13:45 GEC-ESTRO General Assembly	Satellite symposium Varian	Lunch, Satellite Symposia, Poster Viewing			
14:45 – 16:15	<p>Treatment of intermediate-risk prostate cancer patients</p> <p><i>Chair: P. Hoskin (GB)</i> <i>Chair: JP Calatayud (ES)</i></p> <p>Surgery T. de Reijke (NL)</p> <p>Radical / adjuvant external beam</p>	<p>Session on EU Projects</p> <p>ARTFORCE: individualized and safe Radiation treatment C. Rasch (NL)</p> <p>ARTFORCE: Clinical trial in NSCLC: PET boost study W. van Elmpt (NL)</p> <p>ULICE : Union of Light -</p>	<p>ESTRO – ASTRO Joint symposium</p> <p>How high precision technology will change our life</p> <p><i>Chair: J. Bourhis (FR)</i> <i>Chair : A. Zietman (USA)</i></p> <p>High tech radiation therapy: where are the limits?</p>	<p>Clinical Proffered Papers 3: Lung Cancer</p> <p><i>Chair: M. Hatton (GB)</i> <i>Chair: X. Geets (BE)</i></p> <p>A PRACTICAL PREDICTION MODEL FOR OVERALL SURVIVAL FROM STAGE III LUNG CANCER</p> <p><i>Discussant: P. Van Houtte (BE) – 5 min</i></p> <p>INTRA THORACIC</p>	<p>Inter-fraction (between fractions) challenges – Organ deformation and motion</p> <p><i>Chair: C. Garibaldi (IT)</i> <i>Chair: M. Partridge (GB)</i></p> <p>Image registration and dose warping for inter-fraction deformation K. Brock (CA)</p>	<p>Joint with GEC ESTRO</p> <p>Brachytherapy - imaging and dose adaptation</p> <p><i>Chair: P. Papagiannis (GR)</i> <i>Chair: A. Bidmead (GB)</i></p> <p>Status of MR, CT, and US imaging in brachytherapy G. Lowe (GB)</p>	<p>Functional imaging and image technology</p> <p><i>Chair: D. Pasini (IT)</i> <i>Chair: R. Ireland (GB)</i></p> <p>Biological basis of functional Imaging J. Bussink (NL)</p> <p>Image segmentation/ registration in a multi modality platform J. Lee (BE)</p>

	<p>treatment A. Bossi (FR)</p> <p>Permanent seed implantation for intermediate risk prostate cancer: exclusive vs. combined treatment A. Polo (ES)</p> <p>Discussion (15 min)</p>	<p>Ion Centres in Europe: working for hadrontherapy R. Orecchia (IT)</p>	<p>B. Slotman (NL)</p> <p>Targeting concepts: Spatial, molecular, physiologic, temporal T. Rich (USA)</p> <p>What is the clinical benefit of 4D adaptive radiotherapy? C. Rasch (NL)</p> <p>Adaptive treatment with molecular imaging D. Zips (DE)</p>	<p>ANATOMICAL CHANGES FOR LUNG CANCER PATIENTS DURING THE COURSE OF IRRADIATION: HOW TO RESPOND? <i>Discussant: P. Van Houtte (BE) – 5 min</i></p> <p>MEDIASTINAL LYMPH NODE POSITION VARIABILITY IN LUNG CANCER PATIENTS TREATED WITH RADIOTHERAPY</p> <p>ADJUVANT RADIOTHERAPY AFTER EXTRAPLEURAL PNEUMONECTOMY FOR MESOTHELIOMA. PROSPECTIVE ANALYSIS OF A MULTIHSTITUTIONAL SERIES</p> <p>DOSE ESCALATION USING 3DCRT IN CONCURRENT SETTING WITH VINORELBINE AND A PLATINUM COMPOUND IN LOCALLY ADVANCED NSCLC</p> <p>RADIOCHEMOTHERAPY FOR LOCALLY-ADVANCED NSCLC: WHICH IS THE BEST ASSOCIATION? FROM CHEMOTHERAPY TO BIOLOGICAL TARGET IN 5 PHASES II TRIALS C. Ramella (IT)</p>	<p>Dose mapping algorithms and errors J. Siebers (USA)</p> <p>Non-Rigid dose summation with respect to organ deformation between fractions. T. Piotrowski (PO)</p>	<p>Overview of studies on organ interfraction variations in brachytherapy T. Paulsen Hellebust (NO)</p> <p>Dose adaptation by modern treatment planning concepts including inverse planning P. Trnkova (AT)</p>	<p>Use of PET-CT in RT planning A. Osztavics (AT)</p>
16:15 – 16:45	Coffee break						
16:45 – 18:00	<p>GEC Proffered papers 7: Head and Neck</p> <p><i>Chair: G. Kovacs (DE) Chair: C. Coyle (GB)</i></p> <p>ESTRO-Nucletron Brachytherapy Award</p> <p>LIMITED-VOLUME PERIOPERATIVE HDR BRACHYOTHERAPY AS A SUBSTITUTE FOR WIDE-FIELD EBRT IN RESECTED HEAD & NECK CANCER</p> <p>HIGH DOSE RATE BRACHYOTHERAPY IN LIP CARCINOMA</p> <p>LONG-TERM RESULTS IN EYELID CARCINOMA TREATED BY INTERSTITIAL LDR BRACHYOTHERAPY. ANALYSIS OF 60 CASES</p> <p>BRACHYOTHERAPY IN LIP CARCINOMA: LONG-TERM</p>	<p>GEC Proffered Papers 8: Gynecological Cancer</p> <p><i>Chair: R. Pötter (AT) Chair: TBC</i></p> <p>IMAGE GUIDED INTERSTITIAL PDR BRACHYOTHERAPY FOR LOCALLY ADVANCED PRIMARY OR RECURRENT GYNAECOLOGICAL CANCER</p> <p>CLINICAL OUTCOME OF PATIENTS TREATED WITH TEMPLATE BASED HIGH DOSE RATE (HDR) INTERSTITIAL BRACHYOTHERAPY BOOST IN GYNECOLOGICAL MALIGNANCIES</p> <p>VAGINAL VAULT BRACHYOTHERAPY IN ENDOMETRIAL CANCER: IMPROVING OUTCOMES WITH IMAGE GUIDED</p>	<p>ESTRO – CARO Joint symposium</p> <p>Translating research in imaging into clinical practice</p> <p><i>CChair: M. Parliament (CA) Chair: V. Grégoire (BE)</i></p> <p>From genomics to individualized treatment B. Wouters (CA)</p> <p>Translating Molecular imaging into the clinic: from mouse to man P. Lambin (NL)</p> <p>Dose painting: how and for which tumors?</p>	<p>Clinical Proffered Papers 4: Breast Cancer</p> <p><i>Chair: K. Vallis (GB) Chair: E. Lartigau (FR)</i></p> <p>RISK OF SECOND MALIGNANCIES (SM) AFTER BREAST CANCER (BC) TREATMENT AND THEIR RELATIONSHIP WITH THE ADJUVANT RADIOTHERAPY: LONG TERM RESULTS</p> <p>SECOND PRIMARY CANCER AMONG DANISH WOMEN WITH EARLY BREAST CANCER TREATED WITH POSTOPERATIVE RADIOTHERAPY T. Grantzau (DK)</p> <p><i>Discussant: K. Trott (GB) – 5 min for first two trials</i></p>	<p>Physics Proffered Papers 7: IMRT planning and optimisation</p> <p><i>Chair: B. Sánchez-Nieto (Chili) Chair: H. Mayles (GB)</i></p> <p>EFFECTS OF SETUP CORRECTIONS ON THE DOSE DISTRIBUTION OF SBRT OF LUNG CANCER: DOSE INVARIANCE INVALID BUT THE PTV CONCEPT HOLDS</p> <p>PROBABILISTIC DOSE PAINTING BY NUMBERS: COMPARING ACTUAL WITH PRESCRIBED DOSE USING THE IVH</p> <p>BEAM ANGLE OPTIMIZATION USING DERIVATIVE-FREE ALGORITHMS</p>	<p>Physics Proffered Papers 8: Functional Imaging</p> <p><i>Chair: M. Alber (DE) Chair: A. Hounsell (GB)</i></p> <p>GEOMETRICAL ROBUSTNESS OF DIFFUSION WEIGHTED MR IMAGING OF THE PROSTATE</p> <p>IMPROVING THE ROBUSTNESS OF QUANTITATIVE DYNAMIC CONTRAST-ENHANCED MRI FOR TUMOR DELINEATION IN PROSTATE CANCER</p> <p>MULTI-MODALITY MR IMAGING FOR PROSTATE CANCER DETECTION IN CORRELATION TO WHOLE-MOUNT HISTOPATHOLOGY</p> <p>SEGMENTATION OF DCEMR IMAGES OF CERVICAL CANCERS USING K-MEANS</p>	<p>RTT Proffered Papers 4: Imaging for Treatment Planning and Position Verification</p> <p><i>Chair: M. Kamphuis (NL) Chair: G. Whitfield (GB)</i></p> <p>A RELIABLE AND FAST (REAL-TIME) POSITIONING SYSTEM (NAVOTEKÁ®) REDUCES THE OVERALL TIME PER TREATMENT SESSION.</p> <p>INTERFRACTION DISPLACEMENT OF PELVIC LYMPH NODES DURING RADIOTHERAPY FOR BLADDER CANCER</p> <p>AUTO-ADAPTIVE, APERTURE-BASED IGRT, IGRT</p>

	<p>RESULTS</p> <p>EFFICACY AND SAFETY OF HIGH DOSE RATE INTERSTITIAL BRACHYTHERAPY BOOST IN 88 PATIENTS WITH HEAD NECK CANCERS</p> <p>RUTHENIUM PLAQUE BRACHYTHERAPY FOR UVEAL MELANOMA</p> <p>BRACHYTHERAPY IN CHILDREN WITH RHABDOMYOSARCOMAS OF THE NASOLABIAL FOLD: TREATMENT RESULTS OF 16 CASES</p>	<p>APPLICATOR PLACEMENT</p> <p>VAGINAL BRACHYTHERAPY WITH MRI GUIDANCE: TARGET VOLUME DEFINITION AND EFFECT OF BLADDER FILLING ON DOSE TO ORGANS AT RISK</p> <p>IN VIVO DOSIMETRY FOR GYNAECOLOGICAL BRACHYTHERAPY BASED ON A NOVEL RADPOS SYSTEM</p> <p>CORRELATION BETWEEN IN-VIVO DOSIMETRY AND 3D DOSE VOLUME PARAMETERS IN PDR BRACHYTHERAPY OF CERVICAL CANCER</p> <p>LONG TERM FOLLOW-UP AFTER CHEMORADIATION AND HIGH DOSE RATE BRACHYTHERAPY AS CONSERVATIVE FOR VULVAR CANCER</p>	<p>V. Khoo (GB)</p> <p>Real time IGART with linac MR hybrid</p> <p>G. Fallone (CA)</p>	<p>USING PATHOLOGY AND OUTCOME DATA TO ANALYZE THE DEPENDENCE OF AGE ON RADIOTHERAPY RESPONSE IN BREAST-CONSERVING THERAPY</p> <p>CURRENT STATUS OF ELIOT STUDIES ON BREAST CANCER AT THE EUROPEAN INSTITUTE OF ONCOLOGY IN MILAN</p> <p>R. Orecchia (IT)</p> <p>TARGETED INTRAOPERATIVE RADIOTHERAPY – THE TARGIT-A TRIAL UPDATE</p> <p>F. Wenz (DE)</p> <p>RESULTS OF AN ISORT POOLED ANALYSIS WITH LINAC-BASED IORT WITH ELECTRONS (IOERT) AS BOOST STRATEGY DURING BREAST CONSERVING THERAPY IN LIMITED STAGE BREAST CANCER</p> <p>F. Sedlmayer (AT)</p> <p><i>Discussant: F. Vicini (USA) – 10 min for last 3 trials</i></p>	<p>A STUDY OF ICRU 83 GUIDELINES FOR DOSE REPORTING OF H&N IMRT PATIENTS.</p> <p>DOSIMETRIC COMPARISON OF IMRT USING HELICAL PHOTON BEAMS VERSUS RANGEMODULATED ELECTRON BEAMS IN RADIOTHERAPY OF BREAST AND CHEST WALL CANCER</p> <p>FULLY INTEGRATED COMPUTERIZED OPTIMIZATION OF BEAM ANGLES AND FLUENCES IN (NON)-COPLANAR IMRT AND IMPLICATIONS FOR VMAT</p> <p>PERIPHERAL DOSES IN PROSTATE CANCER RADIOTHERAPY: A COMPARISON BETWEEN IMRT AND RAPIDARC TREATMENTS</p>	<p>CLUSTERING FOR OUTCOME PREDICTION</p> <p>DOSE PAINTING BY CONTOURS VERSUS DOSE PAINTING BY NUMBERS FOR LOCALLY ADVANCED LUNG TUMOURS; PRACTICAL IMPLICATIONS OF USING A BROAD OR SHARP BRUSH</p> <p>AUTOMATIC TUMOUR CONTOURING USING FUZZY C-MEANS CLUSTERING AND SUV THRESHOLDS IN PET/CT FOR ESOPHAGEAL CANCER PATIENTS</p> <p>DOSE RESPONSE OF NORMAL LUNG DURING RT ASSESSED BY CONE BEAM CT - A POTENTIAL TOOL FOR BIOLOGICALLY ADAPTIVE RADIATION THERAPY</p>	<p>A COMPARISON OF TREATMENT AND IMAGE MATCH TIME FOR THREE DIFFERENT IGRT PROCEDURES IN RT OF BLADDER CANCER</p> <p>HOW TO IMPROVE IMAGE QUALITY OF ELECTRONIC PORTAL IMAGING DEVICES WITH MLG CALIBRATION AND TEMPERATURE CORRECTION</p> <p>QUANTIFICATION OF DIFFUSION-WEIGHTED MRI FOR TREATMENT RESPONSE ASSESSMENT IN HEAD AND NECK CANCER</p> <p>GLIOBLASTOMA DOSE PAINTING WITH IMRT SIMULTANEOUS INTEGRATED BOOST GUIDED BY MR SPECTROSCOPY</p>
20:00	Social evening						

WEDNESDAY, 11 MAY 2011

	EIOF Capital Hall	EIOF Room 10+11+12	11 th Biennial Physics Auditorium	11 th Biennial Physics Room 7+8+9	11 th Biennial RTT Room 2+3+4	11 th Biennial Young Room 6+13
08:00 – 08:40	<p>30 years of radiation oncology in Prostate cancer - What is the evidence-based that 'we' have created?</p> <p><i>Chair: A. Horwich (GB)</i> <i>Chair: H. Marsiglia (ES)</i></p> <p>Dose escalation: how big is the advantage? D. Dearnaley (GB)</p> <p>Prostate cancer: adjuvant androgen deprivation therapy in the era of new technologies and dose escalation M. Bolla (FR)</p> <p>Salvage or adjuvant radiation therapy after prostatectomy T. Wiegel (DE)</p>	<p>30 years of radiation oncology & Normal tissue - What is the evidence that 'we' have created?</p> <p><i>Chair: I. Turesson (SE)</i> <i>Chair: E. Deutsch (FR)</i></p> <p>Fractionation: clinical application of radiobiological knowledge M. Joiner (USA)</p> <p>Pathogenesis and repair of normal tissue damage W. Doerr (DE)</p>	<p>The tumour microenvironment</p> <p><i>Chair: G. Zwierzchowski (PO)</i></p> <p>A. Van Der Kogel (NL)</p>	<p>Physical processes in proton and ion therapy</p> <p><i>Chair: J. Pawelke (DE)</i> L. Sihver (SE)</p>	<p>Scope of Practice in the New Core Curriculum for RTs</p> <p><i>Chair: B. Bak (PO)</i></p> <p>M. Coffey (IE)</p>	<p>How to get your radiotherapy physics and technology paper published, read and cited?</p> <p><i>Chair: L. Muren (DK)</i></p> <p>How to convert good material into a good paper in a physics or clinical journal? D. Thwaites (GB)</p> <p>Panel discussion: All you wanted to ask your editor M. Alber (DE), D. Thwaites (GB), B. Mijnheer (NL)</p>
08:45 – 10:00	<p>ESTRO-EAU Joint symposium</p> <p>Prostate Cancer - What is the evidence-based that is being created right now? The best of clinical trials</p> <p><i>Chair: PA Abrahamsson (SE)</i> <i>Chair: R. Valdagni (IT)</i></p> <p>Options and outcome of salvage treatment after radiotherapy G. Ahlgren (SE)</p> <p>Will our guidelines be reshaped by: robotic surgery? V. Ficarra (IT)</p> <p>Will our guidelines be reshaped by: particle beams? A. Zietman (USA)</p>	<p>Normal tissue - What is the evidence-based that is being created right now?</p> <p><i>Chair: F. Stewart (NL)</i> <i>Chair: EM Ozsahin (CH)</i></p> <p>Introduction F. Stewart (NL)</p> <p>Late reactions: Which molecular pathways are involved? MC Vozenin-Brotans (FR)</p> <p>Vascular mediated normal tissue damage and strategies for inhibition of this process M. Hauer-Jensen (USA)</p> <p>Oxidative stress in radiation-induced normal tissue damage and strategies for inhibition of</p>	<p>Brachytherapy - dosimetry and dose calculation</p> <p><i>Chair: T. Major (HU)</i> <i>Chair: A. Daggart (GB)</i></p> <p>Image based post dosimetry as a part of advanced QA procedures after seeds implantation in prostate brachytherapy G. Zwierzchowski (PO)</p> <p>Comparisons of conventional and contemporary treatment planning systems in brachytherapy P. Papagiannis (GR)</p> <p>New developments with Monte Carlo calculations for brachytherapy M. Rivard (USA)</p>	<p>Risk assessment and dosimetry in proton and ion therapy</p> <p><i>Chair: A. Bridier (FR)</i> <i>Chair: C. Baker (GB)</i></p> <p>Are there risks associated with proton therapy? – Range, dosimetry and RBE A. Lomax (CH)</p> <p>Prospects and challenges of in-vivo range verification in proton therapy A. Knopf (CH)</p> <p>Absolute and relative dosimetry for protons and ions– challenges and solutions H. Palmans (GB)</p>	<p>Joint with Physics</p> <p>Clinical audits in radiotherapy</p> <p><i>Chair: J. Malicki (PO)</i> <i>Chair: E. Aird (GB)</i></p> <p>European guidelines - 2009 recommendation by European Commission H. Jarvinen (Helsinki)</p> <p>Clinical comprehensive audits - an IAEA project and current development M. Coffey (IE)</p> <p>Implementation of Clinical Audits in radiotherapy in EU member states in the light of new EC recommendation M. Bogusz-Czerniewicz (PO)</p>	<p>PhD in medical physics, and then...? – some 'in-vivo' experiences</p> <p><i>Chair: G. Gagliardi (SE)</i> <i>Chair: C. Clark (GB)</i></p> <p>The benefits and challenges of an international PhD followed by work in a hospital environment (20 min) V. Panettieri (GB)</p> <p>The benefits and challenges of having clinical training first then a PhD (20 min) P. Carrasco (ES)</p> <p>Combining research and clinical work without a formal PhD programme (20 min) C. Garibaldi (IT)</p>

	Will our guidelines be reshaped by: brachytherapy? P. Hoskin (GB)	this process J. Williams (USA)				To PhD or not to PhD, that is the question (15 min) C. Clark (GB)
10:00 – 10:30	Coffee break					
10:30 – 11:45	<p>ESTRO-EAU Joint session</p> <p>Prostate Cancer - Vision for the future: What 'we' will ask for in the new grant applications? - Translational research / High technology <i>Chair: F. Guedea (ES)</i> <i>Chair: PA Abrahamsson (SE)</i></p> <p>Beyond stage, PSA and Gleason Score: genetic prognostic factors J. Schalken (NL)</p> <p>Beyond stage, PSA and Gleason Score: Wait and see randomised trial: A. Widmark (SE)</p> <p>Beyond stage, PSA and Gleason Score: biological and functional imaging J. Barentsz (NL)</p>	<p>Normal tissue - Vision for the future: What 'we' will ask for in the new grant applications? - Translational research / High technology <i>Chair: C. Petersen (DE)</i> <i>Chair: S. Magrini (IT)</i></p> <p>Prediction and prognosis of normal tissue radiation injury J. Alsner (DK)</p> <p>Stem cell / progenitor cell therapy to inhibit radiation injury R. Coppes (NL)</p> <p>Understanding and manipulating cytokine networks involved in development of radiation injury H. Peter Rodemann (DE)</p>	<p>Physics Proffered Papers 8: Highlights - Small and non-reference field Dosimetry <i>Chair: H. Palmans (GB)</i> <i>Chair: R. Thomas (GB)</i></p> <p>EVALUATION OF THE ANISOTROPIC ANALYTICAL ALGORITHM FOR SMALL FIELD DOSIMETRY AND ITS INFLUENCE IN RAPIDARC DELIVERY</p> <p>NEW HIGH RESOLUTION 2D LIQUID FILLED IONIZATION CHAMBER ARRAY FOR SMALL FIELD MEASUREMENTS</p> <p>DOSIMETRIC STUDY AND ARRAY ASSESSMENT OF PLASTIC SCINTILLATION DETECTORS IN STEREOTACTIC RADIOSURGERY CONDITIONS</p> <p>COMPARISON OF DIODE, DIAMOND AND SCINTILLATION DETECTORS FOR THE MEASUREMENT OF SMALL FIELD OUTPUT FACTORS</p> <p>SMALL FIELD MANAGEMENT FOR RAPIDARC DELIVERY: COMPARISON BETWEEN MEASUREMENTS AND CALCULATIONS</p> <p>EXPERIMENTAL SMALL FIELD OUTPUT FACTOR ANALYSIS FOR VARIOUS DIODEDETECTOR AND ACCELERATOR COMBINATIONS</p> <p>THE USE OF ALANINE/EPR FOR THE CALIBRATION OF HELICAL TOMOTHERAPY BEAMS</p>	<p>Physics Proffered Papers 9: Challenges in Treatment Planning <i>Chair: M. do Carmo Lopes (PT)</i> <i>Chair: C. Deehan (GB)</i></p> <p>BENCHMARK OF A NEW ALGORITHM FOR DOSE CALCULATION IN RT USING A GRIDBASED BOLTZMANN EQUATION SOLVER</p> <p>FUNCTIONAL FORMS FOR PHOTON SPECTRA OF CLINICAL LINACS</p> <p>VOXEL BASED METHOD TO GENERATE CT EQUIVALENT IMAGES FROM MR IMAGES FOR TREATMENT PLANNING PURPOSES</p> <p>A VIRTUAL SOURCE MODEL FOR CONE BEAM CT DOSE DEPOSITION</p> <p>FEASIBILITY OF CBCT-BASED DOSE CALCULATION: COMPARISON OF THREE HU ADJUSTMENT TECHNIQUES</p> <p>COMPARISON OF DVH-PARAMETERS FOR DOSE CALCULATION BY TG43 AND BOLTZMANN BASED ALGORITHM ACUROS</p> <p>4D DOSE CALCULATION FOR SCANNED PROTON BEAMS USING A DEFORMING DOSE GRID AND SIMULATED 4DCT</p>	<p>Physics Proffered Papers 10: Monitoring Treatment Parameters <i>Chair: J. Cygler (CA)</i> <i>Chair: S. Blake (GB)</i></p> <p>ONLINE DETECTION OF IMPOSED BRACHYTHERAPY ERRORS IN A PHANTOM USING FIBERCOUPLED LUMINESCENCE DOSIMETRY</p> <p>AN ANALYTICAL APPROACH TO ACCEPTANCE CRITERIA FOR QUALITY ASSURANCE OF INTENSITY MODULATED RADIOTHERAPY</p> <p>REAL-TIME VERIFICATION OF MLC-DRIVEN RADIOTHERAPY USING AN OPTICAL ATTENUATION BASED FLUENCE MONITOR</p> <p>AN INDEPENDENT DOSE CALCULATION PROGRAM FOR THE CHECKING OF TOMOTHERAPY PLANS</p> <p>INITIAL EXPERIENCE WITH A NOVEL ON-LINE BEAM MONITORING SYSTEM</p> <p>TOWARDS AUTOMATIC QUALITY ASSURANCE (QA) OF VOLUMETRIC MODULATED ARC THERAPY (VMAT)</p> <p>INVESTIGATION OF DIFFERENT PIXEL DETECTORS FOR LASER-DRIVEN ACCELERATED PARTICLE BEAMS</p>	<p>Young scientists ESTRO Poster Session</p> <p></p> <p>14 groups of posters in different topics presented by the authors and discussed by a chair in designated poster areas</p>
11:50 – 12:45	<p>Honorary Members Award lectures</p> <p><i>Chair: V. Grégoire (BE)</i> <i>Chair: V. Valentini (IT)</i></p> <p>THE BEST OF TWO WORLDS (25 min) A. Chiti (IT)</p> <p>HEAD NECK CANCER: PROMISES, PITFALLS, CHALLENGES & OPPORTUNITIES (25 min) J.P. Agarwal (India)</p>					

12:45 – 14:30	Lunch, Satellite Symposia, Poster Viewing					From 12:45-14:15 Lunch Symposium for Young Scientists: What can young ESTRO members do for ESTRO and what can ESTRO do for its young members
14:30– 16:00	<p>ESTRO-ESMO-ESSO-ECCO Presidential symposium Clinical Oncology: The future of Radiotherapy, Medical Oncology and Surgical Oncology</p> <p><i>Chair: TBC</i> <i>Chair: J. Bourhis (FR)</i></p> <p><i>Founding member award</i> Clinical Oncology: The future of Radiotherapy and Medical Oncology, Lancet April 18, 1981. Status then and now (30-years later) – did the wishes come true? M. Peckham (GB)</p> <p>Clinical Oncology in Europe 2011 and beyond D. Kerr (GB)</p> <p>Clinical Oncology in Europe 2011 and beyond P. Naredi (SE)</p> <p>Clinical Oncology in Europe 2011 and beyond J. Bourhis (FR)</p> <p>Clinical Oncology in Europe 2011 and beyond M. Baumann (DE)</p>	<p>Clinical Proffered Papers 5: Prostate & Gynaecology</p> <p><i>Chair: M. Krengli (IT)</i> <i>Chair: E. Janulionis(LT)</i></p> <p>FIVE-YEAR SURVIVAL IN A RANDOMIZED PHASE III TRIAL OF CONCURRENT RADIOCHEMOTHERAPY WITH 5-DAY VERSUS WEEKLY CISPLATIN IN LOCALLY ADVANCED CERVICAL CANCER</p> <p><i>Discussant: P. Symonds (GB) – 5 min</i></p> <p>IMPORTANT MORTALITY REDUCTIONS BY SHORT TERM ANDROGEN DEPRIVATION AND RADIO THERAPY FOR LOCALLY ADVANCED PROSTATE CANCER: 10 YEAR TRIAL DATA FROM TROG 96.01</p> <p><i>Discussant: R. de Crevoisier (FR) – 5 min</i></p> <p>PHASE III PILOT STUDY OF DOSE ESCALATION USING CONFORMAL RADIO THERAPY IN PROSTATE CANCER: LONG TERM FOLLOW UP</p> <p><i>Discussant: R. de Crevoisier (FR) – 5 min</i></p> <p>A DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIAL WITH MAGNESIUM OXIDE TO REDUCE PROSTATE MOTION FOR PROSTATE CANCER RADIO THERAPY</p> <p>SALVAGE OR ADJUVANT? 5Y-RESULTS OF THE AIRO NATIONAL WORKING GROUP ON PRO STATE RADIO THERAPY. A MULTICENTER PROSPECTIVE STUDY</p> <p>HYPOFRACTIONATED TOMOTHERAPY TREATMENT (HTT) IN PROSTATE CANCER LYMPH NODAL RELAPSE</p>	<p>Highlights in ESTRO physics</p> <p><i>Chair: T. Knöös (SE)</i> <i>Chair: J. Malicki (PO)</i></p> <p>Birth and growth of physicists contribution in ESTRO A. Dutreix (FR)</p> <p>ESTRO- physics/ developments of meetings, courses, and research programmes during almost 30 years H. Svensson (SE)</p> <p>ESTRO Physics : The past, the present and what's next ? B. Mijnheer (NL)</p>	<p>Normal tissue dose response modeling beyond the QUANTEC project</p> <p><i>Chair: A. Skrobala (PO)</i> <i>Chair: MT Guerrero Urbano (GB)</i></p> <p>DVH-based parameters and models for toxicity prediction J. Deasy (USA)</p> <p>Internal motion and its influence on morbidity prediction for pelvic organs L. Muren (DK)</p> <p>Image-based dose-volume effects prediction C. Fiorino (IT)</p>	<p>Improvement of staff and patient environment</p> <p><i>Chair: G. McColl (NL)</i> <i>Chair: M. Coffey (GB)</i></p> <p>Healing Environment for Cancer Patients A. van den Berg (NL)</p> <p>The art of healing in health care-transforming lives through art B. Devlin (GB)</p> <p>Effect of Light and nature view on patients and staff in a radiotherapy department M. Mast (NL)</p>	

		DETECTED BY 11CCHOLINE PET/CT				
		OPTIMAL DOSES AND REGIMENS OF DISTANT RADIOTHERAPY IN PATIENTS WITH BONE METASTASES.				
16:00 – 16:30	Coffee break					
16:30 – 17:45	<p>Accessibility of RT resources in Europe and the World</p> <p><i>Chair: J. Bourhis (FR)</i> <i>Chair: V. Valentini (IT)</i> <i>Chair: V. Gregoire (BE)</i></p> <p>AVAILABILITY OF RADIOTHERAPY RESOURCES WORLDWIDE: THE IAEA DIRECTORY OF RADIOTHERAPY CENTRES (DIRAC)</p> <p>50 YEARS OF THE IAEA DOSIMETRY LABORATORY WORK FOR RADIOTHERAPY</p> <p>STATE OF RADIATION ONCOLOGY IN THE UK K. Benstead (GB)</p> <p>ORION: SIMPLE AND EFFECTIVE METHOD FOR SYSTEMIC ANALYSIS OF EVENT OCCURRING IN HOSPITAL PRACTICE</p> <p>FAST TRACK FOR HEAD AND NECK CANCER PATIENTS: THE STORY OF THE DANISH NATIONAL STRATEGY FOR ACCELERATED DIAGNOSIS AND TREATMENT OF CANCER</p>	<p>Clinical Proffered Papers 6: Normal Tissue Effects and Quality of Life</p> <p><i>Chair: W. Dörr (DE)</i> <i>Chair: TBC</i></p> <p>ASSOCIATION OF BREAST TUMOUR BED SEROMA WITH POST-OPERATIVE INFECTION AND LATE NORMAL TISSUE TOXICITY: RESULTS FROM THE CAMBRIDGE BREAST IMRT TRIAL</p> <p>QOL / OUTCOMES OF AN INTERNATIONAL PHASE 3 TRIAL OF INTERMITTENT V CONTINUOUS HORMONE THERAPY FOR RELAPSED PROSTATE CA</p> <p>PREDICTIVE DOSIMETRIC FACTORS FOR HIGH-GRADE ESOPHAGITIS IN PATIENTS TREATED FOR NON-SMALL CELL LUNG CANCER (NSCLC) WITH DEFINITIVE 3D CONFORMAL THERAPY (3D-CRT), INTENSITY MODULATED RADIATION THERAPY (IMRT), OR PROTON BEAM THERAPY (PBT) D. Gomez (USA)</p> <p>RECOVERY OF SALIVARY GLAND TOXICITY: CONTRALATERAL PAROTID GLAND (PG) VERSUS BILATERAL SUPERFICIAL LOBES PAROTID SPARING IMRT (PARSPORT VERSUS PARSPORT II)</p> <p>THIRD INTERNATIONAL CONSENSUS ON PALLIATIVE RADIOTHERAPY: A JOINT ASTRO, ESTRO, CARO & TROG INITIATIVE</p> <p>TEETH: THE POORLY DEFINED ORGAN-AT-RISK</p>	<p>Physics Proffered Papers 11: In vivo and online dose measurements</p> <p><i>Chair: W. van Elmpt (NL)</i> <i>Chair: S. Thomas (GB)</i></p> <p>TREATMENT PLANNING SYSTEM BASED EXIT DOSIMETRY</p> <p>DEVELOPMENT OF FLEXIBLE IN-VIVO DOSIMETRY ARRAY</p> <p>EVALUATION OF ONEDOSEPLUSTM MOSFET DOSIMETER FOR IN VIVO DOSIMETRY IN HIGH ENERGY X-RAY BEAMS</p> <p>CAPABILITIES OF RADPOS, 4D IN VIVO DOSIMETRY SYSTEM</p> <p>FROM 2D TO 3D DOSE EVALUATION FOR IN VIVO IMRT VERIFICATION</p> <p>TOMOTHERAPY IN-VIVO DOSIMETRY FOR PROSTATE TREATMENT YIELDS EXCELLENT RESULTS</p> <p>ANGULAR CORRECTION OF THE IN-VIVO RECTUM PROBE READINGS IN ROUTINE GYNECOLOGICAL BRACHYTHERAPY TREATMENT</p>	<p>Physics Proffered Papers 12: Image registration and segmentation</p> <p><i>Chair: D. Sarrut (FR)</i> <i>Chair: C. Moore (GB)</i></p> <p>CLINICAL EVALUATION OF A SPEED OF SOUND ABERRATION CORRECTION ALGORITHM IN QUANTITATIVE ULTRASOUND-AIDED IMAGE GUIDED RADIOTHERAPY</p> <p>A NOVEL METHOD FOR MEGAVOLTAGE SCATTER CORRECTION IN CONE-BEAM CT ACQUIRED CONCURRENT WITH ROTATIONAL IRRADIATION</p> <p>AUTOMATIC BLADDER SEGMENTATION ON CBCT FOR ONLINE ART OF BLADDER CANCER</p> <p>A NOVEL CT-BASED CONTRAST ENHANCEMENT TECHNIQUE FOR MARKERLESS LUNG TUMOR TRACKING IN X-RAY PROJECTION IMAGES</p> <p>ADAPTIVE RADIOTHERAPY TREATMENT FOR PATIENTS WITH ATELECTASIS BASED ON PORTAL DOSIMETRY AND REPEATED CONEBEAM CT</p> <p>ADAPTIVE LIVER SBRT: DAILY RE-PLANNING TO COMPENSATE FOR NON-RIGID ANATOMY CHANGES IMPROVES DOSE DISTRIBUTIONS</p> <p>TRACKING LATENCY IN KV IMAGE-BASED DYNAMIC MLC TRACKING WITH DIRECT IMAGE ACCESS</p>	<p>RTT Proffered Papers 5: Patient Care</p> <p><i>Chair: D. Routsis (GB)</i> <i>Chair: J. Cunningham (IE)</i></p> <p>RTOG 9601: SALVAGE RT & ANTI-ANDROGEN THERAPY IN PROSTATE CANCER PATIENTS WITH ELEVATED PSA AFTER SURGERY</p> <p>A SOCIETY AND COLLEGE OF RADIOGRAPHERS UK SURVEY OF RADIOTHERAPY SKIN CARE</p> <p>BREAST CANCER PATIENTS' KNOWLEDGE BASE OF RADIOTHERAPY- DEVELOPING AN E-KNOWLEDGE TEST</p> <p>EVALUATING THE EFFECT OF CAPHOSOL IN REDUCING ORAL MUCOSITIS IN HEAD AND NECK CANCER PATIENTS UNDERGOING CHEMORADIOTHERAPY OR RADIOTHERAPY</p> <p>PATIENT GROUP DIRECTIONS: FACILITATING EFFICIENT RADIOTHERAPY SERVICE AND PATIENT CARE</p> <p>HEALTH STATUS EVALUATION OF CHILDREN WITH BRAIN TUMORS WHO WERE TREATED BY CRANIOSPINAL IRRADIATION</p> <p>CLINICAL IMPLEMENTATION OF A PROTOCOL FOR PATIENTS CARRYING A PACEMAKER OR ICD RECEIVING RADIOTHERAPY</p>	
17:45	ESTRO General Assembly					

	EIOF Capital Hall	EIOF Room 10+11+12	11 th Biennial Physics Auditorium	11 th Biennial Physics Room 7+8+9	11 th Biennial RTT Room 2+3+4
08:00 – 08:40	<p>30 years of radiation oncology in Gynecological cancer - What is the evidence that 'we' have created? – Update on randomized trials and Meta-analyses</p> <p><i>Chair: TBC</i> <i>Chair: I. Barillot (FR)</i></p> <p>Chemoradiation for cervix cancer: how far have we come? G. Thomas (CA)</p> <p>Cervix cancer: Brachytherapy dose/rate/fractionation C. Haie-Meder (FR)</p> <p>Post-operative adjuvant therapy for endometrial cancer. Recent trials and the way forward PR Blake (GB)</p>	<p>Testis</p> <p><i>Chair: C. Aristei (IT)</i> <i>Chair: C. Belka (DE)</i></p> <p>How we learnt to cure testicular cancer- the road to 2011 M. Williams (GB)</p> <p>The problems caused by curing testicular cancer and survivorship S. Fossa (NO)</p> <p>Learning lessons from the past: the path forward and new opportunities R. Huddart (GB)</p>	<p>The current status of Stereotactic Body Radiotherapy</p> <p><i>Chair: M. Hoogeman (NL)</i></p> <p>Speaker: M. Guckenberger (DE)</p>	<p>Development of procedures for <i>in vivo</i> dosimetry in radiotherapy</p> <p><i>Chair: M. Steiner (CZ)</i></p> <p>P. Mayles (GB)</p>	<p>Focus on target volume delineation of the upper GI track</p> <p><i>Chair: F. Duprez (BE)</i></p> <p>PET in target volume delineation and dose planning for oesophageal cancer C. Muijs (NL)</p> <p>4D-CT and PET in target volume delineation and dose planning for pancreatic cancer M. Cattaneo (IT)</p>
08:45 – 10:00	<p>ESTRO-ESGO Joint symposium</p> <p>Gynecological Cancer - What is the evidence-based that is being created right now?- The best of clinical trials</p> <p><i>Chair: R. Pötter (AT)</i> <i>Chair: A. Van der Zee (NL)</i></p> <p>Cervix and Endometrium Cancer: Imaging/Contouring and Technology (IMRT, IGRT) M. Powell (GB)</p> <p>Cervix Cancer: Image guided adaptive brachytherapy in the setting of definitive radio-chemotherapy – Status of</p>	<p>Ethical issues in managing oncology patients</p> <p>Interactive session Moderators: K. Benstead (GB) and S. Guglani (GB)</p> <p>Discussants: T. Roques (GB) , F. Macbeth (GB) and R. George (GB)</p> <p>Ethical issues/ challenges/ principles in managing cancer patients</p> <p>Cases containing conflict - Individual rights against goals of medicine - Therapeutic momentum against resource constraints</p> <p>Conclusion</p>	<p>Incorporation of molecular and genetic patterns in dose response models</p> <p><i>Chair: G. Meijer (NL)</i> <i>Chair: S. Gulliford (GB)</i></p> <p>Modelling tumour control outcome based on biological imaging response M. Alber (DE)</p> <p>Including molecular and genetic predictors in normal tissue dose-volume modelling T. Rancati (IT)</p> <p>The incorporation of normal tissue functional imaging in dose response studies M. Partridge (GB)</p>	<p>New beam acceleration for proton and ion therapy</p> <p><i>Chair: B. Vojnovic (GB)</i> <i>Chair: K. Kirkby (GB)</i></p> <p>Compact electromagnetic accelerators and beam deliveries for proton and ion therapy M. Schippers (CH)</p> <p>The Dielectric Wall Accelerator: Independent Evaluation of Project Status [1] J. Alonso (USA)</p> <p>Laser driven accelerators for radiobiology experiment J. Pawelke (DE)</p>	<p>Guidelines and protocols in the radiotherapy department</p> <p><i>Chair: C. Beardmore (GB)</i> <i>Chair: U. O'Doherty (GB)</i></p> <p>Staffing and equipment of RT centres: comparing the EORTC, ESTRO and Dutch guidelines C. Hurkmans (NL)</p> <p>Use of pre-treatment imaging protocols for motion estimation B. Bak (PO)</p> <p>The impact of rectal and bladder preparation in prostate radiotherapy L. Mullaney (IE)</p>

	<p>current multi-centre studies J. Lindegaard (DK)</p> <p>Cervix Cancer: Ongoing trials and the GCIG initiative H. Kitchener (GB)</p> <p>Adjuvant treatment of endometrial cancer: Current evidence and ongoing trials C. Creutzberg (NL)</p>				
10:00 – 10:30	Coffee break				
10:30 – 11:45	<p>ESTRO-ESGO Joint symposium</p> <p>Gynecological Cancer - Vision for the future: What 'we' will ask for in the new grant applications? - Translational research / High technology</p> <p><i>Chair: PR Blake (GB)</i> <i>Chair: C. Creutzberg (NL)</i></p> <p>Anti-viral approaches to treat HPV related tumours: The Institute Gustave Roissy experience from pre-clinical data to clinical trials E. Deutsch (FR)</p> <p>Cervix: Technology translational and clinical research R. Pötter (AT)</p> <p>Technological developments and translational research in endometrial cancer treatment: molecular data and image guidance R. Nout (NL)</p> <p>What's new in sentinel lymph node detection in vulvar cancer AGJ van der Zee (NL)</p>	<p>ESTRO - EANM Joint symposium</p> <p>Imaging</p> <p><i>Chair: DC Weber (CH)</i> <i>Chair: A. Chiti (IT)</i></p> <p>PET in Oncology in 2011: where are we coming from? Review of the equipments, tracers, indications, over the last 10-20 years. W. Vogel (NL)</p> <p>PET in radiation oncology in 2011: where are we? Use of different PET radiopharmaceutical for target volume selection and delineation A. Chiti (IT)</p> <p>PET in radiation oncology in the near future: Where are we going to? X. Geets (BE)</p>	<p>How to meet the needs for QA in adaptive radiotherapy?</p> <p><i>Chair: S. Kry (USA)</i> <i>Chair: G. Budgell (GB)</i></p> <p>Economic burden of QA in advanced radiotherapy Y. Lievens (BE)</p> <p>Replacing QA measurement by calculation? J. Olofsson (SE)</p> <p>Patient-specific QA for adaptive radiotherapy W. van Elmpt (NL)</p>	<p>Mobility of medical physicists in the world</p> <p><i>Chair: TBC</i> <i>Chair: G. Lawrence (GB)</i></p> <p>The mobility of medical physicists in Europe: Role of EFOMP W. van der Putten (IE)</p> <p>AAPM: Standardized approach to support quality and mobility in Medical Physics B. Paliwal (USA)</p> <p>IOMP: Global approach to support mobility of medical physicists M. do Carmo Lopes (PT)</p> <p>Roundtable discussion (30 min)</p>	<p>Improving delivery accuracy by using in-room imaging</p> <p><i>Chair: H. Jarvinen (FI)</i> <i>Chair: E. Miles (GB)</i></p> <p>Cone beam CT for use in daily clinical routine: an update C. Machado (PT)</p> <p>Optimizing setup margins by using On-line/Off-line verification protocols F. Moura (PT)</p> <p>Adaptive treatment with Hi-art tomotherapy for locally advanced head and neck squamous cell carcinoma F. Carruthers (BE)</p>
11:45 – 12:45			<p>Debate: Online transmission in vivo dosimetry renders pre-treatment QA obsolete</p>		